Gene News and Research

Latest Gene News and Research

Rituximab alters T-cell metabolism in patients with nephrotic syndrome

Nephrotic syndrome is caused when the filtering system in the kidneys is damaged, allowing large amounts of protein to leak into the urine.

10 Sep 2026

Review highlights solute carriers as targets for central nervous system disorders

Solute carriers (SLCs) are specialized transport proteins that control the movement of nutrients, ions and neurotransmitters across cell membranes and are essential for brain metabolism and neuronal communication.

10 Sep 2026

Rentosertib shifts multiple proteomic aging clocks toward younger age profiles in IPF trial

Researchers applied six proteomic aging clocks to serum samples from a phase 2a trial of rentosertib in people with idiopathic pulmonary fibrosis and found treatment-associated shifts toward younger predicted biological-age profiles, particularly with the 30 mg twice-daily regimen. Additional proteomic analyses linked treatment to changes in senescence, metabolism, growth-factor signaling, and fibrosis-related pathways, although the study could not determine whether these effects reflected genuine geroprotection rather than disease modification.

10 Sep 2026

Yourgene Health launches Insight DPYD assay (IVDR)

Yourgene Health (part of the Novacyt Group), an international molecular diagnostics company with a broad portfolio of integrated technologies and services, announces the commercial launch of its In Vitro Diagnostic Regulation (IVDR)-certified Yourgene® Insight DPYD assay, expanding the Company's clinical genetics portfolio across regulated European markets.

From Yourgene Health 9 Sep 2026

Blood protein profiling could improve rare disease diagnosis

Researchers from Queen Mary University of London, the Berlin Institute of Health at Charité (BIH) and Genomics England have shown that measuring proteins in the blood can provide important additional clues about the effects of genetic variants, helping to identify diagnoses and potential new disease-causing genes that genome sequencing alone has been unable to resolve.

9 Sep 2026

Study links methylglyoxal stress to immunotherapy resistance in triple-negative cancer

The metabolism of cancer cells may play a key role in their ability to evade the immune system. This is demonstrated by a new study conducted by researchers at the University of Liège, which reveals how methylglyoxal stress – a by-product of tumor metabolism – promotes immunosuppression and the formation of metastases, and may contribute to resistance to immunotherapy and the progression of triple-negative cancer.

9 Sep 2026

New base editing techniques accurately modify genes in human embryos

A study by researchers at Columbia University Vagelos College of Physicians and Surgeons has found that new cutting-edge techniques can accurately edit genes in human embryos-giving scientists indispensable tools for understanding normal human development-but has also uncovered important risks that currently preclude the use of the techniques in the clinic.

9 Sep 2026

New genetic map helps track aggressive prostate cancer development

Prostate cancer is the second most common form of cancer among men globally. Yet, we still know relatively little about why the disease develops or why some men live with it for years while in others it progresses aggressively.

9 Sep 2026

Skin microbiome changes may predict infant eczema and food allergies

The first clues that a baby may develop eczema or food allergies could be hiding in the microscopic organisms living on their skin, according to a study led by researchers in Washington State University's College of Veterinary Medicine.

9 Sep 2026

New laser-fabricated plasmonic chip accurately identifies and sorts cancer cells

Novel laser-fabricated plasmonic chip combines 185 nm Raman resolution and deep learning to identify and sort cancer cells with 96.2% accuracy.

9 Sep 2026

EpilepsyGTx and Viralgen collaborate to advance AAV gene therapy program for epilepsy ahead of first-in-human trial

EpilepsyGTx, a biotechnology company developing gene therapies for refractory epilepsy, and Viralgen, a leading contract development and manufacturing organization (CDMO) specializing in recombinant adeno-associated virus (AAV) gene therapies, today announced a partnership to support production of EpilepsyGTx's lead investigational gene therapy program targeting patients with focal refractory epilepsy (FRE), EPY201, ahead of first-in-human clinical trials.

From EpilepsyGTx 9 Sep 2026

AlphaGenome Atlas maps billions of genetic changes with AI

The human genome contains approximately 3 billion DNA letters, creating more than 9 billion possible single-letter changes.

9 Sep 2026

Astrocyte changes may explain how stress affects mental health

A new study led by UCLA Health researchers has identified a specific type of brain cell and a tiny structure on its surface that changes when the body is under stress, which may help explain why stress can lead to anxiety and depression.

8 Sep 2026

UCLA researchers develop scalable TCR therapy for solid tumors

T cell receptor, or TCR, therapy is a cancer treatment that genetically reprograms immune cells, called T cells, to hunt down cancer with precision. It's similar to another treatment, CAR T-cell therapy, but with one key difference: CAR T-cell therapy can only spot proteins that naturally appear outside of a cancer cell.

8 Sep 2026